Ainsliadimer A selectively inhibits IKKα/β by covalently binding a conserved cysteine

Aberrant activation of NF-κB is associated with the development of cancer and autoimmune and inflammatory diseases. IKKs are well recognized as key regulators in the NF-κB pathway and therefore represent attractive targets for intervention with small molecule inhibitors. Herein, we report that a complex natural product ainsliadimer A is a potent inhibitor of the NF-κB pathway. Ainsliadimer A selectively binds to the conserved cysteine 46 residue of IKKα/β and suppresses their activities through an allosteric effect, leading to the inhibition of both canonical and non-canonical NF-κB pathways. Remarkably, ainsliadimer A induces cell death of various cancer cells and represses in vivo tumour growth and endotoxin-mediated inflammatory responses. Ainsliadimer A is thus a natural product targeting the cysteine 46 of IKKα/β to block NF-κB signalling. Therefore, it has great potential for use in the development of anticancer and anti-inflammatory therapies.

[1]  Chao Li,et al.  A biomimetic total synthesis of (+)-ainsliadimer A. , 2010, Organic letters.

[2]  J. Tschopp,et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors , 1997, Nature.

[3]  K. McIntyre,et al.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. , 2003, The Journal of biological chemistry.

[4]  Shao-Cong Sun,et al.  Non-canonical NF-κB signaling pathway , 2011, Cell Research.

[5]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[6]  Q Cheng,et al.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[8]  Chao Li,et al.  Biomimetic syntheses and structural elucidation of the apoptosis-inducing sesquiterpenoid trimers: (−)-ainsliatrimers A and B , 2013 .

[9]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[10]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[11]  S. Gerstberger,et al.  Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation , 1995, Science.

[12]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[13]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[14]  M. Karin,et al.  The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. , 2004, Cancer letters.

[15]  Juan Su,et al.  Ainsliadimer A, a new sesquiterpene lactone dimer with an unusual carbon skeleton from Ainsliaea macrocephala. , 2008, Organic letters.

[16]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[17]  Michael Karin,et al.  Inflammation meets cancer, with NF-κB as the matchmaker , 2011, Nature Immunology.

[18]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[19]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[20]  M. Karin,et al.  Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation , 1996, Molecular and cellular biology.

[21]  Michael Karin,et al.  Regulation and Function of IKK and IKK-Related Kinases , 2006, Science's STKE.

[22]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[23]  Xuliang Jiang,et al.  Crystal structure of inhibitor of κB kinase β (IKKβ) , 2011, Nature.

[24]  Matthew P Jacobson,et al.  Turning a protein kinase on or off from a single allosteric site via disulfide trapping , 2011, Proceedings of the National Academy of Sciences.

[25]  Xiaowei Xu,et al.  Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[27]  A. Hoffmann,et al.  Circuitry of nuclear factor kappaB signaling. , 2006, Immunological reviews.

[28]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[29]  Chao Li,et al.  Biomimetic syntheses of (-)-gochnatiolides A-C and (-)-ainsliadimer B. , 2012, Journal of the American Chemical Society.

[30]  Haruo Okado,et al.  Tumor Necrosis Factor Induces Bcl-2 and Bcl-x Expression through NFκB Activation in Primary Hippocampal Neurons* , 1999, The Journal of Biological Chemistry.

[31]  G. Rastelli,et al.  αC helix displacement as a general approach for allosteric modulation of protein kinases. , 2013, Drug discovery today.

[32]  M. Karin,et al.  The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .

[33]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[34]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[35]  Jiyan Zhang,et al.  Inactivation of BAD by IKK Inhibits TNFα-Induced Apoptosis Independently of NF-κB Activation , 2013, Cell.

[36]  Raymond C Stevens,et al.  Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.

[37]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[38]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.

[39]  Yaxue Zhao,et al.  Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. , 2012, Nature chemical biology.

[40]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[41]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[42]  Dung-Fang Lee,et al.  Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy , 2008, Clinical Cancer Research.

[43]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.